Drs Sarah Hull and Paul Rosser with Zeiss’ Lahiru Gunasena (centre)

The ZEISS Cirrus 6000 OCT device, integrating high-speed imaging and an artificial intelligence (AI)-guided OCT image assessment support tool, received FDA approval just over a month ago, said Lahiru Gunasena, Zeiss product specialist.

Operating at 100,000 A-scans per second, the Cirrus 6000 delivers rapid, high-definition OCT and OCT angiography (OCTA) scans, which facilitate a wider field of view – up to 12mm in a single scan – and reduces motion artefacts, enabling clinicians to capture detailed images swiftly, the company said. The device provides non-invasive visualisation of retinal microvasculature, aiding in the detection and management of conditions such as diabetic retinopathy, age-related macular degeneration and glaucoma.

Its integration into clinical practice supports informed decision-making, efficient workflows and improved patient outcomes, said Gunasena. “The goal is integration and digital interconnectivity into the Zeiss ecosystem. That includes the Zeiss Forum where all devices 'talk’ to each other, all with one window open. A surgeon can access this information from anywhere and plan their surgeries from abroad.”

The latest Cirrus 6000 software is supported by the largest OCT reference database in the US, comprising 870 healthy eyes with diverse age ranges and optic disc sizes, Zeiss said.

Clinics can run the Cirrus PathFinder 500, 5000 and 6000 via software licence activation, Gunasena said.